Bibliographic Info
GuidelineGuidelines on long-acting injectable cabotegravir for HIV prevention
Year of Publication2022
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Moderate
Long-acting injectable cabotegravir may be offered as an additional prevention choice for people at substantial risk of HIV infection, as part of combination prevention approaches
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations
Year2022
InstitutionWHO